86620-81-7

Basic information

• Product Name: 4-PIPERAZIN-1-YLMETHYL-BENZOIC ACID METHYL ESTER
• Synonyms: AKOS B022240;4-(1-PIPERAZINYL METHYL) BENZOIC ACID METHYL ESTER;4-(1-PIPERIYL METHYL) BENZOIC ACID METHYL ESTER;4-PIPERAZIN-1-YLMETHYL-BENZOIC ACID METHYL ESTER;ART-CHEM-BB B022240;METHYL 4-PIPERAZIN-1-YLMETHYLBENZOATE;METHYL 4-PIPERAZINE-1-YLMETHYLBENZOATE;4-(1-PIPERAZIYL METHYL) BENZOIC ACID METHYL ESTER
• CAS NO: 86620-81-7
• Molecular Formula: C₁₃H₁₈N₂O₂
• Molecular Weight: 234.29
• Product Categories: API intermediates
• Mol File: 86620-81-7.mol
• Article Data: 11

Chemical Properties

• Boiling Point: 355.6 ºCat 760 mmHg
• Flash Point: 168.9 ºC
• Appearance: /
• Density: 1.117 g/cm³
• Vapor Pressure: 3.08E-05mmHg at 25°C
• Refractive Index: 1.544
• Storage Temp.: 2-8°C(protect from light)
• CAS DataBase Reference: 4-PIPERAZIN-1-YLMETHYL-BENZOIC ACID METHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 4-PIPERAZIN-1-YLMETHYL-BENZOIC ACID METHYL ESTER(86620-81-7)
• EPA Substance Registry System: 4-PIPERAZIN-1-YLMETHYL-BENZOIC ACID METHYL ESTER(86620-81-7)

Safety Data

• Hazardous Substances Data: 86620-81-7(Hazardous Substances Data)

Usage

General Description

4-PIPERAZIN-1-YLMETHYL-BENZOIC ACID METHYL ESTER is a chemical compound that is derived from piperazine and benzoic acid. It is commonly used in the pharmaceutical industry as an intermediate in the synthesis of various drugs and pharmaceuticals. 4-PIPERAZIN-1-YLMETHYL-BENZOIC ACID METHYL ESTER exhibits a range of biological activities, including antipsychotic, antihistaminic, and anxiolytic effects. It is also used as a building block in the production of other organic compounds. Due to its versatile properties, 4-PIPERAZIN-1-YLMETHYL-BENZOIC ACID METHYL ESTER plays a crucial role in the development and production of numerous medications and pharmaceutical products.

InChI:InChI=1/C13H18N2O2/c1-17-13(16)12-4-2-11(3-5-12)10-15-8-6-14-7-9-15/h2-5,14H,6-10H2,1H3

Upstream product

• 1571-08-0 methyl 4-formylbenzoate 
• 110-85-0 piperazine 
• 34040-64-7 p-methyloxycarbonylbenzyl chloride 
• 619-66-9 4-Carboxybenzaldehyde 
• 2417-72-3 Methyl 4-(bromomethyl)benzoate 
• 844891-11-8 tert-butyl 4-[(4-methoxycarbonylphenyl)methyl]piperazine-1-carboxylate 
• 142-64-3 piperazine dihydrochloride 
• 142-63-2 piperazine hexahydrate 

Downstream Products

• 895519-97-8 4-((4-ethylpiperazin-1-yl)methyl)benzoic acid 
• 208754-40-9 4-((4-propylpiperazin-1-yl)methyl)benzoic acid 
• 415951-48-3 C₁₅H₂₂N₂O₂ 
• 86620-80-6 Methyl 4-[1-(2-hydroxypropyl)-piperazin-4-ylmethyl]-benzoate 

Relevant articles and documents

Synthesis, biological evaluation, and molecular docking of ((4-([1,2,4]triazolo[4,3-b][1,2,4,5]tetrazin-6-yl) piperazin-1-yl)methyl) benzohydrazide derivatives

A series of ((4-([1,2,4]triazolo[4,3-b][1,2,4,5] methyl) benzo-hydrazide derivatives was designed, synthesized, and evaluated for their inhibition activities against five tumor cells and c-Met kinase in vitro. These compounds were fully characterized by

ROR [gamma]t inhibitor, preparation method and application thereof

The invention relates to the technical field of medicines, in particular to an ROR [gamma]t inhibitor, a preparation method and application thereof. The invention also relates to a pharmaceutical composition containing the compound, a method for preparing the pharmaceutical composition, and application of the compound or the pharmaceutical composition in treatment or prevention of ROR [gamma]t-mediated cancers, inflammations or autoimmune diseases of mammals, especially human beings.

Benzamide capped peptidomimetics as non-ATP competitive inhibitors of CDK2 using the REPLACE strategy

Inhibition of cyclin dependent kinase 2 (CDK2) in complex with cyclin A in G1/S phase of the cell cycle has been shown to promote selective apoptosis of cancer cells through the E2F1 pathway. An alternative approach to catalytic inhibition is to target the substrate recruitment site also known as the cyclin binding groove (CBG) to generate selective non-ATP competitive inhibitors. The REPLACE strategy has been applied to identify fragment alternatives and substituted benzoic acid derivatives were evaluated as a promising scaffold to present appropriate functionality to mimic key peptide determinants. Fragment Ligated Inhibitory Peptides (FLIPs) are described which potently inhibit both CDK2/cyclin A and CDK4/cyclin D1 and have preliminary anti-tumor activity. A structural rationale for binding was obtained through molecular modeling further demonstrating their potential for further development as next generation non ATP competitive CDK inhibitors.